Future University In Egypt (FUE)
Future University is one of most promising private universities in Egypt. Through excellence in teaching, research and service, Future University strives to provide a comprehensive, high-quality education that prepares our graduates to be future leaders.
90th Street
New Cairo

Mona El Assal

Basic information

Name : Mona El Assal
Title: Associat Professor of Pharmaceutics at Pharmaceutics and Pharmaceutical Technology department at FUE University.
Google Schoolar Link
Personal Info: Dr. Mona Ebrahim. Associat Professor of Pharmaceutics at Pharmaceutics and Pharmaceutical Technology department.She got her Master and Doctoral degree from Cairo University View More...


Certificate Major University Year
PhD Pharmaceutics and Clinical Pharmacy. Cairo University 2005
Masters Pharmaceutics and Clinical Pharmacy. Cairo University. 2000
Bachelor Pharmaceutical Sciences Cairo University 1984

Teaching Experience

Name of Organization Position From Date To Date
Military Medical Academy Consultant of Army Pharmaceutical Industry and Lecturer 01/01/1992 01/01/2011

Researches /Publications


Mona Ebrahim Abdel Tawab Ahmed Elassal



ABSTRACT Objective: The evolution of antimicrobial resistance is a universal obstacle that necessities the innovation of more effective and safe antimicrobial alternatives with synergistic properties. The purpose of this study was to investigate the possible improvement of cephalexin antimicrobial treatments by loading into chitosan-based nanoparticles, then evaluate their antibacterial and antibiofilm activities as well as determination of its cytotoxicity. Methods: Chitosan nanoparticles (CSNPs) were prepared by ionic gelation method. Parameters were studied to optimize the particle size of CSNPs including pH, stirring rate, homogenization and ultra-sonication time. Size was measured by transmission electron microscope (TEM) and Zeta sizer, morphology seen by scanning electron microscope (SEM). Entrapment efficiency, drug loading and drug content were calculated. Stability of both plain and loaded chitosan Nano-carriers, Drug release and Kinetics also compatibilities were studied. Antimicrobial activity of CSNPs and cephalexin loaded CSNPs were evaluated against 4 Gram-positive and 4 Gram-negative standard and clinical isolates by microdilution method, also assessment of antibiofilm activity of both formulas was investigated against two biofilm producers clinical isolates by tube assay in addition to determination of their cytotoxicity by MTT(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Results: Chitosan nanoparticles and its loaded antibiotics proved compatible combination with small Zeta size, suitable Zeta potential, maximum EE% and drug-loading capacity, sustained controlled release properties followed diffusion kinetic model and six month stability studies. Cephalexin loaded CSNPs showed better antimicrobial activity than plain CSNPs. Synergistic effects were found against S. aureus (ATCC 25923), B. subtilis (ATCC 9372), S. epidermidis, E. faecalis, P. aeruginosa (ATCC 29853) in addition to two carbapenem resistant isolates k. pneumoniae and E. coli. Also cephalexin loaded CSNPs exhibited antibiofilm activity against E. faecalis clinical isolate. Even though, cephalexin loaded CSNPs exhibited significant antibacterial activity, it showed less toxicity against mammalian cells, it had IC50 equal to 231.893 and did not exhibit any cytotoxicity against the WI-38 fibroblast cells at concentration 23.4 Conclusion: Cephalexin loaded CSNPs possessed good stability and sustained release effect in addition to its antimicrobial, antibiofilm activities and reduced cytotoxicity

Download PDF

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona I. El-Assal1*, Ahmed Abdel Bari2 and Mohamed Rafat3


The present study is to examine In-vivo pharmacodynamics antidiabetic effect following oral administration of the selected optimized microcapsules in comparison with oral metformin solution. Solid dispersions microcapsules were prepared using solvent evaporation method which enclosed preparation of a uniform dispersion of Metformin HCl in (Hydroxy propyl methylcellulose k100, Ethyl cellulose, Eudragit RL PO, Eudragit RS PO and Compritol 888 ATO). A two-factor, General factorial statistical design was used to quantitate the effect of polymer type(X1) and drug: polymer ratio(X2) on the release profile. Where polymer type and drug: polymer ratio were selected as independent variables, while Y1 (cumulative drug release after 1 h) and Y2 (cumulative drug release in 3 h), Y3 (cumulative drug release in10 h),Y4 (angle of repose ) and Y5(Hausner ratio) were selected as dependent variables. A convenient statistical model was made and a significantly controlled release rate was exhibited. The solid dispersions were characterized for their in vitro- release rate. The oral administration of formulae (T20) which consists of metformin HCl and compritol 888 ATO) in drug/polymer ratio (1:4) was chosen as optimum formula resulted in a clear long lasting Statistically significant anti-hyperglycemic effect up to 12 h as compared to diabetic control Group and metformin HCl solution treated group. Factorial design suggested only one optimized combination of the polymer by which maximum desirability obtained. The oral administration of formulae (T20) resulted in a clear long lasting statistically significant anti-hyperglycemic effect.

Download PDF
Proniosomes as Nano-Carrier for Transdermal Delivery of Atenolol Niosomal Gel - 01/1

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel Tawab Ahmed El-Assal


Objective of the study is to prepare Proniosomes that refers to a flexible vesicular carrier with the potential for drug administration through the transdermal route. Medthod: Proniosomes were prepared by the coacevation-phase separation technique The prepared formulations were evaluated for vesicle size, entrapment efficiency. The optimal poniosomes formula (A8) was prepared with different aqueous phase, incorporated in a gel base and studied for pH, viscosity, spredapility, stability, in vitro drug release and ex vivo permeation. Results: Niosomes formulations prepared with Span 40 and 60 have spherical and smaller Nano size. 25 mg atenolol loading has resulted 190.9 ± 15.033 nm sizes. EE% of the optimum formula prepared with distilled water was 62.11 to 92.38 .Rheological behavior showed combined shear thinning and thixotropic and gel was spreadable . Tested formulations were stable on cooling (4-8 oC) . In vitro drug release followed zero order kinetic, and gave sustained release. Release rate was significantly higher across cellulose membrane compared with rate skin. Amount of drug obtained after skin extraction was 92.6 ± 0.5% indicate enhanced permeation rate. Conclusion: All the proniosomal gel formulations were found through the acceptable range of vascular size and entrapment efficiency. Formulation A8 has been selected as an optimized therapeutic system of atenolol.

Download PDF
Olmesartan medoxomil-loaded mixed micelles: Preparation, - 01/1

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mohamed A. El-Gendy a, Mona I.A. El-Assal a, *, Mina Ibrahim Tadros b,


Olmesartan medoxomil (OLM) is highly lipophilic in nature (log p ¼ 4.31) which attributes to its low aqueous solubility contributing to its low bioavailability 25.6%. OLM was loaded into mixed micelles carriers in a trial to enhance its solubility, thus improving its oral bioavailability. OLM-loaded mixed micelles were prepared, using a Pluronic® mixture of F127 and P123, adopting the thin-film hydration method. Three drug: Pluronic® mixture ratios (1:40, 1:50and 1: 60) and various F127: P123 ratios were prepared. OLM Loaded mixed micelles showed stability up to 12 h. The particle size of the systems varied from 364.00 nm (F3) to 13.73 nm (F18) with accepted Poly dispersity index (PDI) values. The in-vitro release studies of OLM from mixed micelles versus drug aqueous suspension were assessed using the reverse dialysis technique in a USP Dissolution tester apparatus (type II). The highest RE% (43%) was achieved with OLM-loaded mixed micelles (F8) when compared to (35%) of drug suspension. © 2017 Future University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

Download PDF
Effect of Tinidazole on Norfloxacin Disposition - 01/1

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel tawab ElAssal and sally Ali Helmy


Co-administration of norfloxacin (NFX) and tinidazole (TNZ) has been used for the treatment of gastrointestinal and urinary tract infections. Concomitant oral administration of NFX with TNZ may affect NFX absorption and consequently its blood concentration and pharmacological effect. The present study was undertaken to investigate the effect of TNZ at the usual clinical dosage on the pharmacokinetics of NFX in healthy volunteers. This study was conducted as an open-label, randomized, two-way crossover experimental design. After an overnight fast, subjects were randomized to receive a single oral dose of NFX 400 mg alone and the fixed-dose combination (FDC) of NFX /TNZ 400 mg/600mg on two different occasions separated by 1 week washout period between treatments. Blood samples were collected up to 24 h postdose, and plasma was analyzed for NFX concentrations by using HPLC. The pharmacokinetic properties of NFX after FDC administration were compared with NFX administered alone. Twelve healthy subjects were enrolled (6 in each part), and all subjects completed the study. None of the participants showed any sign of adverse drug reactions during or after the completion of the study. The 90% confidence interval (CI) between NFX alone and when co-administered with TNZ indicated the presence of an interaction between NFX and TNZ, which would significantly increase the systemic rate and exposure of NFX absorption. The co-administration of TNZ with NFX increased the AUC and Cmax of NFX significantly compared with administration of NFX alone. The AUC and Cmax of NFX alone were 6.0 μg.hr/ mL (2.3-9.8) and 0.87 μg/mL (0.4-1.6), respectively whereas the corresponding AUC and Cmax values after administration of FDC were 7.1 μg.hr/mL (4.0-10.6) and 0.97 μg/mL (0.4-1.7), respectively. The respective geometric mean ratios of NFX for AUC and Cmax with TNZ were 1.197 [90% CI, 0.941-1.522] and 1.087 (90% CI, 0.807 -1.463) compared with NFX alone. Both Tmax and Ka of NFX showed a significant decrease after administration of the combination compared to administration of NFX alone. The peak plasma concentration reached at 1.3 h (0.6-2.4) and 1.9 h (0.4-4.4) after oral administration of FDC and NFX alone, respectively. Both NFX and TNZ were well tolerated. The interaction of TNZ with fluroquinolones should be investigated to determine whether this interaction is limited to NFX or if other fluroquinolones have the same pharmacokinetic interactions. Further studies are necessary to determine the role of P-gp and other transporters on NFX disposition and pharmacokinetics. Additionally, the influence of TNZ on the physiological activity of GIT should be investigated.

Download PDF


Award Donor Date
Certificate of Excellence Meletary Medical Services 2005

Follow us on

Visit the Faculty